TIMI (Thrombolysis In Myocardial Infarction) Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, and Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA.
TIMI (Thrombolysis In Myocardial Infarction) Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, and Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA.
J Am Coll Cardiol. 2021 Jun 8;77(22):2822-2845. doi: 10.1016/j.jacc.2021.01.060.
In 1984, the National Heart, Lung, and Blood Institute (NHLBI) decided to study the efficacy and safety of the treatment of acute myocardial infarction with an emerging therapy, coronary thrombolysis, and thus the TIMI (Thrombolysis In Myocardial Infarction) Study Group was born. Following completion of 3 clinical trials of thrombolytic therapy supported by the NHLBI, TIMI became an academic research organization headquartered at Brigham and Women's Hospital and subsequently branched out to study a wide range of patients, including those with stable coronary, cerebrovascular, and peripheral arterial disease; dyslipidemia; heart failure; atrial fibrillation; diabetes; and obesity. TIMI also began to study a wide range of interventions including thrombolytic, antithrombotic, lipid-modifying, anti-inflammatory, heart failure, glucose-lowering, and weight loss agents. TIMI, now in its 37th year, has completed >70 trials. This review describes the origins of the TIMI Study Group, summarizes several of its completed trials and the major lessons learned from them, and discusses ongoing trials and future directions.
1984 年，美国国家心肺血液研究所（NHLBI）决定研究新兴疗法——冠状动脉溶栓治疗急性心肌梗死的疗效和安全性，因此诞生了 TIMI（血栓溶解治疗心肌梗死）研究小组。在 NHLBI 支持的 3 项溶栓治疗临床试验完成后，TIMI 成为一个总部设在布莱根妇女医院的学术研究组织，并随后扩展到研究广泛的患者群体，包括稳定型冠心病、脑血管病和外周动脉疾病患者；血脂异常患者；心力衰竭患者；心房颤动患者；糖尿病患者；肥胖症患者。TIMI 还开始研究广泛的干预措施，包括溶栓、抗血栓、调脂、抗炎、心力衰竭、降糖和减肥药物。TIMI 现在已经进入第 37 个年头，已经完成了超过 70 项试验。本文回顾了 TIMI 研究小组的起源，总结了其完成的几项试验及其从中获得的主要经验教训，并讨论了正在进行的试验和未来的方向。
